Johnson & Johnson confirms opioid business has ended in $230 million settlement
Updated: Oct 31, 2022
Johnson & Johnson has agreed to a $230 million settlement with New York state that bars the company from promoting opioids and confirmed it has ended distribution of such products within the United States.
New York Attorney General Letitia James’ office in a statement Saturday said the agreement bans J&J from promoting opioids through any means and prohibits lobbying about such products at the federal, state or local levels.
Johnson & Johnson has not marketed opioids in the U.S. since 2015 and fully discontinued the business in 2020.
Related article: J&J didn’t tell the FDA that at least three tests by three different labs from 1972 to 1975 had found asbestos in its talc